HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034)
The overall HER2+ gastric cancer market is projected to grow, driven by increasing biomarker testing, better patient selection, and continued advancements in HER2-targeted ADCs, bispecific antibodies, and novel immune-based approaches. Additionally, the launch of therapies such as Zanidatamab (Jazz Pharmaceuticals), Rilvegostomig (AstraZeneca), Evorpacept (ALX Oncology), and others in the future is expected to bring a positive shift in the treatment landscape of HER2+ gastric cancer.
LAS VEGAS, June 9, 2025 /PRNewswire/ -- DelveInsight's HER2+ Gastric Cancer (including GEJ) Market report includes a comprehensive understanding of current treatment practices, emerging HER2+ gastric cancer therapies, market share of individual therapies, and current and forecasted HER2+ gastric cancer market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the HER2+ Gastric Cancer Market Report
As per DelveInsight's analysis, the total market size of HER2+ gastric cancer (including GEJ) in the 7MM is approximately USD 700 million in 2024 and is projected to increase during the forecast period (2025–2034).
In 2024, among the current therapies for HER2+ gastric cancer, the largest revenue was generated by Trastuzumab ± Chemotherapy, i.e., USD 140 million in the United States.
The total number of incident cases of HER2+ gastric cancer in the 7MM accounted for approximately. 45,000 in 2024. These cases are expected to increase by 2034.
Leading HER2+ gastric cancer companies, such as AstraZeneca/Daiichi Sankyo, Merck, Jazz Pharmaceuticals, BeiGene, Zymeworks, Shanghai Henlius Biotech, AbClon, ALX Oncology, Artiva Biotherapeutics, GC Cell, KLUS Pharma, Shanghai Miracogen, Pfizer, Bayer, Enliven Therapeutics, Ambrx, NovoCodex, Mersana Therapeutics, GSK, SystImmune, and others, are developing novel HER2+ Gastric cancer therapies that can be available in the HER2+ gastric cancer market in the coming years.
Daiichi Sankyo and AstraZeneca's ENHERTU (trastuzumab deruxtecan), is the only approved therapy for the treatment of advanced or metastatic HER2+ gastric cancer for 2L therapy. The drug received accelerated approval in January 2021. Along with ENHERTU (trastuzumab deruxtecan), KEYTRUDA (pembrolizumab), and HERCEPTIN (trastuzumab) are approved for HER2+ gastric cancer for 1L therapy.
Daiichi Sankyo and AstraZeneca's ENHERTU is also expanding into the first-line treatment setting, which is expected to increase its patient share and, consequently, drive growth in the market size.
Some of the key HER2+ gastric cancer emerging therapies in the pipeline include ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others.
Data presented during the recent ASCO 2025 meeting showed that ENHERTU extended overall survival for more than 3 months in patients with advanced HER2-positive gastric or GEJA following progression on first-line therapy, based on the Phase III DESTINY-Gastric04 trial.
In February 2025, AstraZeneca anticipated a data readout from the Phase Ib/II (NCT04379596, DESTINY-Gastric03) trial, which was focused on treating metastatic or unresectable HER2+ gastric cancer, GEJ, and GEA, in 2026.
In February 2025, AstraZeneca expected the first patient dosing of ENHERTU (NCT06731478, DESTINY-Gastric05) for HER2+ first-line locally advanced or metastatic gastric cancer or GEJ adenocarcinoma to begin in Q1 2025, with data anticipated to be available after 2026.
In the January 2025 presentation, Jazz Pharmaceuticals anticipated the potential approval and launch of zanidatamab as a first-line treatment for GEA in 2026. Additionally, the company is also looking forward to expanding its market strategy for zanidatamab in 2026.
In January 2025, ALX Oncology presented positive updated data from the ASPEN-06 Phase II clinical trial at the 2025 ASCO Gastrointestinal Cancers Symposium, demonstrating that the company's investigational CD47-blocker, evorpacept, produces a durable clinical response and exhibits a well-tolerated safety profile in patients with previously treated HER2+ advanced gastric cancer or GEJ cancer.
Discover which therapies are expected to grab the HER2+ gastric cancer market share @ HER2+ Gastric Cancer Market Report
HER2+ Gastric Cancer Overview
Gastric cancer is the fifth most common type of cancer and the fourth leading cause of cancer-related deaths worldwide. HER2, also known as HER2/neu or ERBB2, is found in approximately 15–30% of gastric cancers, including those at the Gastroesophageal Junction (GEJ). It is located on chromosome 17q21 and is part of the EGFR family, which includes EGFR/HER1, HER3, and HER4. The ligand for the HER2 tyrosine kinase receptor remains unidentified. HER2 can form both homodimers and heterodimers with other EGFR family receptors, and overexpression of HER2 can result in ligand-independent activation. In gastric cancer, ERBB2 mutations are most commonly found in the CIN subtype, primarily consisting of missense mutations (74%), with smaller proportions of insertions (22%) and fusions (0.7%). HER2 expression is more frequently observed in the intestinal subtype (according to Lauren's classification), as well as in proximal gastric cancer, GEJ cancer, metastatic disease (particularly liver metastasis), and lymph node involvement.
HER2+ Gastric Cancer Epidemiology Segmentation
In the 7MM, in 2024, among all the HER2+ Gastric cancer indications, breast cancer accounted for the highest number of incident cases, while ovarian cancer occupied the bottom of the ladder. The HER2+ gastric cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Incident Cases of Gastric Cancer (including GEJ)
Gender-Specific Cases of Gastric Cancer (including GEJ)
Stage-Specific Cases of Gastric Cancer (including GEJ)
Total Incident Cases of HER2+ Gastric Cancer (including GEJ)
Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ)
HER2+ Gastric Cancer Treatment Market
HER2, which is overexpressed or amplified in 6–36% of gastric cancer patients, represents a key target in the development of novel treatment strategies for metastatic gastric cancer. While surgical resection remains the primary treatment and can cure patients with early-stage cancer, the survival rates for those with advanced resectable gastric or gastroesophageal junction cancers remain low, despite the introduction of new treatments like perioperative chemotherapy or adjuvant chemoradiation. For patients diagnosed with early-stage disease, gastrectomy is the standard treatment. However, survival rates for those with advanced resectable cancers are still poor, even with the addition of new therapies such as perioperative chemotherapy or adjuvant chemoradiation.
Treatment for HER2-positive gastric cancer depends on factors such as tumor size, location, and the patient's overall health. The humanized monoclonal antibody HERCEPTIN (trastuzumab) targets HER2, inhibiting the growth and survival of HER2-dependent tumors. Alongside HERCEPTIN, KEYTRUDA (Merck), one of the first therapies approved for gastric cancer, works by binding to the Programmed Cell Death-1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2, and reversing PD-1 pathway-mediated immune suppression, including the antitumor immune response. Most recent approvals for targeted therapies, such as ENHERTU (Daiichi Sankyo) and AIDIXI (Remegen Biosciences), are used in second- and third-line treatments for gastric cancer.
Learn more about the FDA-approved HER2+ gastric cancer therapies @ HER2+ Gastric Cancer Treatment Drugs
Key Emerging HER2+ Gastric Cancer and Companies
Various new therapies are in development with a focus on the mentioned limitations of the currently approved drugs. Some of the most prominent ones include Evorpacept (ALX Oncology), Zanidatamab (Jazz Pharmaceuticals), IAM1363 (Iambic Therapeutics), ELVN-002 (Enliven Therapeutics), ARX788 (Ambrx), Rilvegostomig (AstraZeneca), and others. These emerging drugs play a vital part in fulfilling the unmet need for the treatment approach of HER2+ gastric cancer.
Although the space is quite active and various trials are underway to treat patients with HER2+ gastric cancer, continuous efforts are further needed to develop novel drugs that would be more effective and less toxic.
ZIIHERA is a bispecific antibody targeting HER2, binding to two extracellular sites on the HER2 protein. In November 2024, the FDA granted accelerated approval for ZIIHERA for adult patients with previously treated, unresectable, or metastatic HER2+ (immunohistochemistry 3+) biliary tract cancer (BTC), identified through an FDA-approved test.
Jazz Pharmaceuticals expects to release top-line data in the second quarter of 2025 from the Phase III HERIZON-GEA-01 trial (NCT05152147), which is assessing zanidatamab combined with chemotherapy, with or without tislelizumab, as a first-line treatment for HER2-positive metastatic gastric and esophageal adenocarcinoma (GEA). According to the presentation, Jazz Pharmaceuticals aims to potentially approve and launch zanidatamab as a first-line treatment for gastric cancer in 2026. The company is also planning to expand its market strategy for zanidatamab in 2026.
HLX22 (AC101), a novel anti-HER2 monoclonal antibody developed by AbClon and further advanced by Henlius, is currently under investigation. In November 2024, Henlius Biotech announced that the first patient was dosed in the Phase III international multicenter clinical trial (HLX22-GC-301) for HLX22. In October 2024, Henlius received approval from Japan's PMDA for the Clinical Trial Notification (CTN) of a Phase III international multicenter study of HLX22, in combination with trastuzumab and chemotherapy, as a first-line treatment for HER2-positive advanced gastric cancer.
The other therapies in the HER2+ gastric cancer pipeline include
TUKYSA (tucatinib): Pfizer
BAY2927088: Bayer
AB-201 (GCC2003, HER2 CAR-NK): Artiva Biotherapeutics and GC Cell
A166 (Trastuzumab botidotin): KLUS Pharma
MRG002: Shanghai Miracogen
AIDIXI (disitamab vedotin): Pfizer
BAY2701439: Bayer
XMT-2056: Mersana Therapeutics and GSK
BL-M07D1: SystImmune
and others
The anticipated launch of these emerging therapies are poised to transform the HER2+ gastric cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the HER2+ gastric cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about HER2+ gastric cancer drug clinical trials, visit @ HER2+ Gastric Cancer Drugs
HER2+ Gastric Cancer Market Dynamics
The HER2+ gastric cancer market dynamics are expected to change in the coming years. HER2-targeted therapies, such as HERCEPTIN, ENHERTU, and anti-PD1 therapy KEYTRUDA, offer more precise treatment by improving efficacy and minimizing side effects compared to traditional chemotherapy. Daiichi Sankyo and AstraZeneca's ENHERTU is expanding into the first-line treatment setting, which is expected to increase its patient share and drive market growth.
There is growing research interest in combining next-generation HER2 inhibitors or bispecific antibodies with Immune Checkpoint Inhibitors (ICIs), presenting significant opportunities to enhance treatment efficacy and improve patient survival. Additionally, the HER2+ gastric cancer market is projected to grow due to increased incidence rates, an aging population, and advancements in treatment methodologies, potentially leading to more investment in research and development.
Furthermore, potential therapies are being investigated for the treatment of HER2+ gastric cancer, and it is safe to predict that the treatment space will significantly impact the HER2+ gastric cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the HER2+ gastric cancer market in the 7MM.
However, several factors may impede the growth of the HER2+ gastric cancer market. HER2+ gastric cancer is an aggressive form of the disease with a significantly high mortality rate, poor survival rates, and a poor prognosis due to factors such as low screening rates, high rates of refractory/relapsed tumors, and the advanced age of patients. The complexity of tumor biology, including intratumoral heterogeneity, poses challenges to effective treatment strategies and limits the efficacy of current therapies. Additionally, HER2+ gastric cancer is prone to developing resistance to targeted therapies, highlighting the need for the continuous development of next-generation agents, which further increases R&D costs.
Moreover, HER2+ gastric cancer treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the HER2+ gastric cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the HER2+ gastric cancer market growth.
HER2+ Gastric Cancer Report Metrics
Details
Study Period
2020–2034
HER2+ Gastric Cancer Report Coverage
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
HER2+ Gastric Cancer Market CAGR
13 %
HER2+ Gastric Cancer Market Size in 2024
USD 700 Million
Key HER2+ Gastric Cancer Companies
AstraZeneca/Daiichi SankyoJazz Pharmaceuticals, BeiGene, Zymeworks, Merck, Shanghai Henlius Biotech, AbClon, ALX Oncology, Artiva Biotherapeutics, GC Cell, KLUS Pharma, Shanghai Miracogen, Pfizer, Bayer, Enliven Therapeutics, Ambrx, NovoCodex, Mersana Therapeutics, GSK, SystImmune, and others
Key HER2+ Gastric Cancer Therapies
ENHERTU, KEYTRUDA, ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK) A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others
Scope of the HER2+ Gastric Cancer Market Report
HER2+ Gastric Cancer Therapeutic Assessment: HER2+ Gastric Cancer current marketed and emerging therapies
HER2+ Gastric Cancer Market Dynamics: Conjoint Analysis of Emerging HER2+ Gastric Cancer Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, HER2+ Gastric Cancer Market Access and Reimbursement
Discover more about HER2+ gastric cancer drugs in development @ HER2+ Gastric Cancer Clinical Trials
Table of Contents
1
Key Insights
2
Report Introduction
3
Executive Summary
4
Epidemiology and Market Methodology
5
HER2+ Gastric Cancer Market Overview at a Glance
5.1
Market Share (%) Distribution of HER2+ Gastric Cancer by Line of Therapies in 2020 in the 7MM
5.2
Market Share (%) Distribution of HER2+ Gastric Cancer by Line of Therapies in 2034 in the 7MM
5.3
Market Share (%) Distribution of HER2+ Gastric Cancer by Therapies in 2020 in the 7MM
5.4
Market Share (%) Distribution of HER2+ Gastric Cancer by Therapies in 2034 in the 7MM
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Molecular Subtypes of Gastric Cancer
7.3
HER2+ Gastric Cancer
7.4
Causes and Risk Factors Related to Gastric Cancer
7.5
Clinical Manifestations Related to Gastric Cancer
7.6
Diagnosis Related to Gastric Cancer
7.7
Staging of Gastric Cancer
7.8
Current Treatment Practices: Gastric Cancer
7.8.1
Treatment for HER2+ Gastric Cancer
8
Guidelines and Recommendations for HER2+ Gastric Cancer
8.1
PAN-ASIAN ADAPTED (PAGA) ESMO CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS, TREATMENT, AND FOLLOW-UP OF PATIENTS WITH GASTRIC CANCER (2024)
8.2
NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES FOR GASTRIC CANCER (2024)
8.3
NICE GUIDELINES FOR OESOPHAGO-GASTRIC CANCER (2023)
8.4
GASTRIC CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP (2022)
8.5
JAPANESE GASTRIC CANCER TREATMENT GUIDELINES (2021)
9
Epidemiology and Patient Population
9.1
Key Findings
9.2
Assumptions and Rationale: 7MM
9.3
Total Incident Cases of Gastric Cancer (including GEJ) in the 7MM
9.4
United States
9.4.1
Total Incident Cases of Gastric Cancer (including GEJ) in the United States
9.4.2
Gender-specific Cases of Gastric Cancer (including GEJ) in the United States
9.4.3
Stage-specific Cases of Gastric Cancer (including GEJ) in the United States
9.4.4
Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in the United States
9.4.5
Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ) in the United States
9.5
EU4 and the UK
9.5.1
Total Incident Cases of Gastric Cancer (including GEJ) in EU4 and the UK
9.5.2
Gender-specific Cases of Gastric Cancer (including GEJ) in EU4 and the UK
9.5.3
Stage-specific Cases of Gastric Cancer (including GEJ) in EU4 and the UK
9.5.4
Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in EU4 and the UK
9.5.5
Total Incident Cases of Advanced HER2+ Gastric Cancer in EU4 and the UK
9.6
Japan
9.6.1
Total Incident Cases of Gastric Cancer (including GEJ) in Japan
9.6.2
Gender-specific Cases of Gastric Cancer (including GEJ) in Japan
9.6.3
Stage-specific Cases of Gastric Cancer (including GEJ) in Japan
9.6.4
Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in Japan
9.6.5
Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ) in Japan
10
Patient Journey
11
Marketed Drug
11.1
Key Competitors
11.2
KEYTRUDA (pembrolizumab): Merck
11.2.1
Product Description
11.2.2
Regulatory Milestones
11.2.3
Other Development Activities
11.2.4
Clinical Development
11.2.5
Safety and Efficacy
11.3
ENHERTU (trastuzumab deruxtecan): Daiichi Sankyo and AstraZeneca
11.3.1
Product Description
11.3.2
Regulatory Milestones
11.3.3
Other Development Activities
11.3.4
Clinical Development
11.3.5
Safety and Efficacy
12
Emerging Therapies
12.1
Key Cross Competition
12.2
ZIIHERA (zanidatamab): Jazz Pharmaceuticals, BeiGene, and Zymeworks
12.2.1
Product Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.4
Safety and Efficacy
12.3
Rilvegostomig: AstraZeneca
12.3.1
Product Description
12.3.2
Clinical Development
12.4
HLX22 (AC101): Shanghai Henlius Biotech and AbClon
12.4.1
Product Description
12.4.2
Other Development Activity
12.4.3
Clinical Development
12.4.4
Safety and Efficacy
12.5
Evorpacept (ALX148): ALX Oncology
12.5.1
Product Description
12.5.2
Other Developmental Activities
12.5.3
Clinical Development
12.5.4
Safety and Efficacy
12.6
TUKYSA (tucatinib): Pfizer
12.6.1
Product Description
12.6.2
Other Development Activity
12.6.3
Clinical Development
12.6.4
Safety and Efficacy
13
HER2+ Gastric Cancer (including GEJ): 7MM Analysis
13.1
Key Findings
13.2
Market Outlook
13.3
Conjoint Analysis
13.4
Key Market Forecast Assumptions
13.4.1
Cost Assumptions and Rebates
13.4.2
Pricing Trends
13.4.3
Analogue Assessment
13.4.4
Launch Year and Therapy Uptake
13.5
Total Market Size of HER2+ Gastric Cancer (including GEJ) in the 7MM
13.6
United States Market Size
13.6.1
Total Market Size of HER2+ Gastric Cancer (including GEJ) in the United States
13.6.2
Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in the United States
13.7
EU4 and the UK Market Size
13.7.1
Total Market Size of HER2+ Gastric Cancer (including GEJ) in EU4 and the UK
13.7.2
Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in EU4 and the UK
13.8
Japan Market Size
13.8.1
Total Market Size of HER2+ Gastric Cancer (including GEJ) in Japan
13.8.2
Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in Japan
14
Unmet Needs
15
SWOT Analysis
16
KOL Views
17
Market Access and Reimbursement
17.1
United States
17.1.1
Centre for Medicare and Medicaid Services (CMS)
17.2
EU4 and the UK
17.2.1
Germany
17.2.2
France
17.2.3
Italy
17.2.4
Spain
17.2.5
United Kingdom
17.3
Japan
17.3.1
MHLW
17.4
Market Access and Reimbursement of HER2+ Gastric Cancer (including GEJ)
18
Appendix
18.1
Bibliography
18.2
Report Methodology
19
DelveInsight Capabilities
20
Disclaimer
Related Reports
HER2+ Gastric Cancer Pipeline
HER2+ Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2+ gastric cancer companies, including Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo, AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, among others.
HER2+ Gastric Cancer Epidemiology
HER2+ Gastric Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the HER2+ gastric cancer epidemiology trends.
Gastric Cancer Market
Gastric Cancer Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key gastric cancer companies, including Hanmi Pharmaceuticals, Merck, Minneamrita Therapeutics, Taiho Pharmaceuticals, Bayer, among others.
Gastric Cancer Pipeline
Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gastric cancer companies, including EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech, CARsgen Therapeutics Co., Ltd., Zymeworks Inc., NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/her2-gastric-cancer-including-gej-market-to-increase-at-a-remarkable-growth-rate-of-13-during-the-study-period-20202034--delveinsight-302476182.html
SOURCE DelveInsight Business Research, LLP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
3 hours ago
- Wall Street Journal
Asian Currencies Consolidate as Traders Assess U.S.-China Agreement
0117 GMT — Asian currencies consolidate against the dollar in the morning session as traders assess the U.S.-China agreement on a framework to ease trade tensions. Representatives from the two countries said the framework would essentially restore a pact they agreed to in Switzerland last month, a deal that saw both sides reduce tariffs. However, the negotiators refrained from disclosing exactly what they had agreed to as part of the framework, which may result in continued uncertainty over the trade truce. USD/JPY is steady at 144.91; USD/KRW edges 0.1% lower to 1,364.40; AUD/USD is 0.1% lower at 0.6519. (
Yahoo
4 hours ago
- Yahoo
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
The most recent trading session ended with Astrazeneca (AZN) standing at $73.83, reflecting a +1.12% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily gain of 0.55%. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Heading into today, shares of the pharmaceutical had gained 5.89% over the past month, outpacing the Medical sector's gain of 3.49% and lagging the S&P 500's gain of 6.29% in that time. Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company is predicted to post an EPS of $1.11, indicating a 12.12% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $14.03 billion, indicating an 8.42% upward movement from the same quarter last year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $4.49 per share and a revenue of $57.68 billion, representing changes of +9.25% and +6.67%, respectively, from the prior year. Investors should also pay attention to any latest changes in analyst estimates for Astrazeneca. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.06% lower within the past month. As of now, Astrazeneca holds a Zacks Rank of #3 (Hold). Investors should also note Astrazeneca's current valuation metrics, including its Forward P/E ratio of 16.25. This denotes a discount relative to the industry's average Forward P/E of 19.92. We can additionally observe that AZN currently boasts a PEG ratio of 1.34. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.43. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 76, finds itself in the top 31% echelons of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Gas Ignition Control Market is expected to reach USD 6.4 billion by 2034, with a 6.4% CAGR
Gas Ignition Control Market Outlook 2025-2034 Luton, Bedfordshire, United Kingdom, June 10, 2025 (GLOBE NEWSWIRE) -- The global gas ignition control market is experiencing significant expansion, with its valuation estimated at approximately USD 3.5 billion in 2024. Over the forecast period, the market is expected to grow at a compound annual growth rate (CAGR) of 6.4%, reaching a projected value of USD 6.4 billion by 2034. This substantial growth trajectory is primarily fueled by advancements in safety technologies, the rise in automation, and increasing adoption of smart systems across residential, commercial, and industrial applications. Download PDF Brochure: As governments and regulatory bodies enforce stricter safety standards and environmental regulations, the demand for reliable, efficient, and intelligent gas ignition control systems continues to rise. These systems play a crucial role in ensuring the safe and efficient operation of gas-powered equipment, ranging from residential heaters and stoves to large-scale industrial machinery. Market Segmentation and Key Components By Product Type The market comprises a range of components, with Ignition Control Modules leading the segment by accounting for around 30% of total market share. These modules are essential in ensuring precise timing and safety during ignition processes, especially in modern gas appliances. The ongoing transition toward smart home ecosystems continues to elevate the demand for these intelligent modules. Gas Flame Sensors, which detect the presence or absence of flame to prevent gas leaks or explosions, represent 25% of the market. Their usage is rapidly expanding as safety becomes a top priority, particularly in automated and industrial settings. Control Valves, responsible for regulating gas flow and pressure, hold a 20% share and are seeing growing interest due to innovations enhancing precision and sustainability. Ignition Transformers, with a 15% share, are primarily used in industrial applications and are critical for producing the high-voltage sparks needed for ignition. By Application In terms of application, residential heating systems dominate with nearly 40% of total usage. Consumers increasingly prefer energy-efficient and eco-friendly gas heating solutions, which has driven innovation in ignition controls tailored for home appliances. Commercial applications, including restaurants and food service equipment, account for around 30%, where high efficiency and compliance with health and safety codes are essential. Industrial usage holds approximately 20% of the market and focuses on heating and process control systems in manufacturing facilities. The segment benefits from automation and process reliability. Meanwhile, the automotive sector, though smaller at 10%, is gradually expanding as hybrid and natural gas vehicles become more prevalent and fuel systems evolve to meet emission standards. By End User and Technology Among end users, the residential sector leads in terms of market share, driven by the increasing adoption of gas-based heating and cooking systems in households. Commercial and industrial users follow closely, with growing emphasis on automation, safety, and operational efficiency. In terms of technology, innovations such as Electronic Ignition, Hot Surface Ignition, and Piezoelectric Ignition have transformed performance benchmarks, enabling real-time system responsiveness and safer ignition cycles. Browse full Report - Market Segmentation By Product Type: Ignition Control Modules Gas Flame Sensors Control Valves Ignition Transformers By Application: Residential Heating Commercial Appliances Industrial Processes Automotive By End User: Residential Commercial Industrial By Technology: Piezoelectric Ignition Electronic Ignition Hot Surface Ignition By Region: North America Latin America Europe Asia-Pacific Middle East & Africa Key Market Drivers The steady growth of the gas ignition control market can be attributed to several crucial factors. One of the foremost drivers is the increasing emphasis on safety. Whether in households or heavy industries, users are prioritizing systems that minimize the risk of gas leaks and explosions. Advanced ignition control mechanisms offer not only improved safety but also enhanced operational reliability. Secondly, the integration of smart technologies and IoT features is reshaping the market. Real-time monitoring and diagnostics, predictive maintenance, and automatic fault reporting are just a few of the intelligent functions driving consumer preference. These capabilities are especially beneficial in industrial settings, where uptime and performance reliability are critical. The supportive regulatory environment is another major catalyst. Governments across the globe are imposing stringent safety regulations and environmental mandates, prompting the need for upgraded ignition systems that comply with new standards. For example, emission control laws are leading manufacturers to develop eco-friendly and energy-efficient ignition systems. Challenges and Restraints Despite the promising outlook, the market does face challenges. A primary hurdle is the high initial cost of installing advanced ignition control systems. This can be a deterrent, especially in cost-sensitive markets or for smaller enterprises. While the long-term operational benefits are compelling, the upfront investment remains a significant barrier for widespread adoption. Raw material price fluctuations and supply chain disruptions also pose threats. Given the reliance on specialized components, any volatility in global trade or materials sourcing can impact production timelines and cost structures. Additionally, regulatory compliance—while necessary—can strain resources. Frequent updates to standards may require manufacturers to re-engineer products or allocate funds toward continuous testing and certification. Opportunities and Emerging Trends Despite these challenges, the market is rich in growth opportunities. One major area is the development of integrated, smart ignition systems. Companies that can create end-to-end solutions with built-in diagnostics, remote control, and energy optimization stand to gain significantly. The shift in consumer behavior towards sustainable living is also encouraging the adoption of low-emission ignition systems. A promising trend is the rise of subscription-based service models, especially in commercial and industrial sectors. These models offer customers continued access to upgrades, maintenance, and support—making advanced systems more accessible without high upfront costs. Additionally, there's growing potential in renewable energy integration, as ignition systems evolve to work alongside cleaner fuel sources and hybrid systems. Buy Now: Regional Market Insights Asia-Pacific The Asia-Pacific region leads the global market, commanding approximately 45% of the total revenue. Rapid urbanization, industrial growth, and infrastructural development in countries such as China, India, and South Korea drive this dominance. The region's large population base and rising energy demand make it a hotspot for gas ignition system deployment. Additionally, regulatory initiatives around safety and pollution control contribute to increased adoption. North America North America follows with 30% market share, supported by a strong industrial base and advanced consumer markets. Strict safety regulations in the U.S. and Canada fuel demand for next-generation ignition systems. The region is also home to several leading technology developers and enjoys an established distribution network. Europe Europe holds about 20% of the market, characterized by its commitment to green energy and emissions control. Countries like Germany and the UK are spearheading the adoption of sustainable and smart gas systems. The European market is also driven by smart home trends and regulatory incentives for cleaner energy usage. Latin America and Middle East & Africa Emerging regions like Latin America and the Middle East & Africa offer notable growth potential, with Latin America forecasted to grow at a CAGR of 6.2%. Infrastructure expansion and improved access to energy solutions are key drivers. However, these regions face challenges related to political instability, limited technological access, and inconsistent regulatory environments. Recent Developments and Strategic Moves Key Competitors Honeywell International Inc. Siemens AG Emerson Electric Co. Schneider Electric SE Johnson Controls International plc UTC (United Technologies Corporation) Rockwell Automation, Inc. ABB Ltd. General Electric Company Intertek Group plc Ansul LLC (part of Tyco Fire Protection) Kidde (part of Carrier Global Corporation) CEA (Continental Engineering Associates) Xtralis (a part of Honeywell) Fluke Corporation 1. Honeywell International Inc. Month/Year: January 2023 Type of Development: Product Launch Detailed Analysis: In January 2023, Honeywell launched a new gas ignition control system aimed at enhancing safety and reliability in commercial heating applications. The significance of this development lies in its advanced technology that reduces the risk of ignition failure and enhances system efficiency. This launch is particularly impactful in markets with stringent safety regulations, as modern industrial facilities increasingly seek to minimize operational risks associated with gas usage. Honeywell's competitive edge over other players may widen due to the innovative features such as remote monitoring capabilities and integration with IoT devices. As industry trends favor smart automation, this product places Honeywell at the forefront of a transformational shift towards more integrated and intelligent safety solutions in gas management systems. 2. Siemens AG Month/Year: March 2023 Type of Development: Partnership Detailed Analysis: In March 2023, Siemens AG entered a strategic partnership with a leading cybersecurity firm to enhance the security of its gas ignition control systems used in industrial settings. This collaboration is significant as cyber threats have become a growing concern in industrial automation and control systems. Enhanced cybersecurity measures can boost customer confidence, thereby increasing market penetration as clients prioritize security alongside operational efficiency. This development might lead to competitive shifts, with companies that fail to prioritize cybersecurity potentially losing their market positions. As Siemens strengthens its position, this partnership may prompt industry-wide shifts towards prioritizing integrated security features in gas ignition technologies. 3. Emerson Electric Co. Month/Year: May 2023 Type of Development: Acquisition Detailed Analysis: In May 2023, Emerson Electric Co. announced the acquisition of a startup specializing in gas ignition technology, bolstering its product portfolio significantly. This acquisition is pivotal as it enables Emerson to incorporate advanced ignition solutions, further solidifying their presence in the gas safety market. By bringing in innovative technologies and expertise, Emerson aims to accelerate the development of smarter ignition systems. This strategic move might lead to an overarching trend of consolidation within the industry, as other players may seek acquisitions to enhance their technological capabilities and competitive positioning. Emerson's expanded capabilities could also redefine market dynamics, as customers increasingly demand integrated solutions. 4. General Electric Company Month/Year: July 2023 Type of Development: Technological Advancement Detailed Analysis: In July 2023, General Electric announced significant technological advancements in their gas ignition controls, incorporating machine learning algorithms to enhance system performance and predictive maintenance capabilities. This move highlights the growing trend of digital transformation within the industry, where data analytics are leveraged to improve safety and operational efficiency. The ability to predict potential failures before they occur represents a competitive edge, as clients are seeking solutions that not only ensure compliance but also optimize uptime and reduce unforeseen maintenance costs. As GE sets this standard, competitors may be compelled to innovate rapidly to catch up, indicating a potential shift in technological benchmarks across the market. 5. Johnson Controls International plc Month/Year: September 2023 Type of Development: Expansion Detailed Analysis: In September 2023, Johnson Controls announced its expansion into the Indian market with the opening of a state-of-the-art facility dedicated to manufacturing gas ignition control systems. This strategic move is highly significant as India is witnessing rapid industrial growth and increasing focus on safety regulations. By investing in local manufacturing, Johnson Controls not only reduces operational costs but also tailors its products to meet regional demands more effectively. This expansion is likely to alter competitive dynamics in the region, as an increased local presence could lead to more competitive pricing and quicker response times for customers. Moreover, this may encourage other multinational companies to enhance their investments in India, leading to a more competitive landscape for gas safety technologies in the region. This report is also available in the following languages : Japanese (ガス点火制御市場), Korean (가스 점화 제어 시장), Chinese (燃气点火控制市场), French (Marché du contrôle de l'allumage du gaz), German (Markt für Gaszündungssteuerungen), and Italian (Mercato del controllo dell'accensione del gas), etc. Request Sample Pages: More Research Finding – Chemical Enhanced Oil Recovery EOR IOR Market The global Enhanced Oil Recovery (EOR) market is valued at approximately $51 billion in 2024, with projections indicating a substantial growth trajectory, potentially reaching around $86 billion by 2034. This growth corresponds to a Compound Annual Growth Rate (CAGR) of approximately 5.3% during the forecast period of 2025-2034. Cryogenic Equipments Market The cryogenic equipment market is poised for significant growth, with a current market value estimated at approximately $20.5 billion in 2024. Projections indicate this market will reach nearly $32.7 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 4.6% during the forecast period from 2025 to 2034. Heat Exchangers Market The heat exchangers market is expected to grow at 5.1% CAGR from 2022 to 2029. It is expected to reach above USD 23.22 billion by 2029 from USD 15.6 billion in 2021. Turbines Market The global turbine market is valued at approximately $210 billion, demonstrating robust growth due to rising energy demands and a shift towards renewable energy solutions. The projected market value for 2025 is estimated at $225 billion, with an expected increase to around $320 billion by 2034. This indicates a Compound Annual Growth Rate (CAGR) of approximately 4.5% over the forecast period from 2025 to 2034. Natural Gas Market The global natural gas market is projected to reach approximately $4.1 trillion in 2024, driven by an increasing demand for cleaner energy sources and technological advancements in extraction and processing. The market is expected to grow significantly during the forecast period from 2025 to 2034, reaching an estimated value of $6.5 trillion by 2034. This growth corresponds to a Compound Annual Growth Rate (CAGR) of about 5.0% over the next decade. Ion Introduction Instrument Market The global ion introduction instrument market is anticipated to reach a value of approximately $1.2 billion in 2024. This sector is expected to grow significantly, with a projected market value of around $2.5 billion by 2034, reflecting the increasing demand for efficient ionization techniques in various applications, including pharmaceuticals, environmental monitoring, and food safety. Veterinary Surgical Stapler Market The global veterinary surgical stapler market is estimated to reach approximately $600 million in 2024, driven by the increasing incidence of surgeries in veterinary practices and advances in surgical technologies. Over the forecast period from 2025 to 2034, the market is projected to grow to about $950 million, reflecting a Compound Annual Growth Rate (CAGR) of around 5.5%. Multi Instrument Access Device Under Endoscope Market The global market for Multi Instrument Access Devices Under Endoscope is valued at approximately $1.2 billion in 2024 and is projected to reach around $2.5 billion by 2034, driven by advancing technologies and increasing adoption of minimally invasive procedures. This translates to a compound annual growth rate (CAGR) of about 7.6% during the forecast period from 2025 to 2034. Electrogastrogram Apparatus Market The electrogastrogram (EGG) apparatus market is poised for significant growth, valued at approximately $150 million in 2024. Forecasts suggest a robust expansion, projecting a market value of nearly $300 million by 2034. This indicates a compound annual growth rate (CAGR) of about 7.3% from 2025 to 2034. Gastroesophageal Reflux Therapeutic Instrument Market The gastroesophageal reflux (GER) therapeutic instrument market is projected to reach a value of approximately $3.5 billion in 2024, driven by increasing prevalence of gastroesophageal reflux disease (GERD) and advancements in therapeutic technologies. Over the forecast period from 2025 to 2034, this market is expected to grow at a robust Compound Annual Growth Rate (CAGR) of 6.2%, projecting a market value of about $6.5 billion by 2034. Urinary Guide Wire Market The global urinary guide wire market is projected to reach approximately $240 million in 2024, driven by increasing rates of urinary tract disorders and advancements in minimally invasive surgical techniques. The market is expected to grow significantly, with a projected value of about $450 million by 2034, highlighting an anticipated Compound Annual Growth Rate (CAGR) of 6.6% during the forecast period from 2025 to 2034. Purstring Autosuture Purse String Device Market The market for autosuture purse string devices is projected to be valued at approximately $350 million in 2024, with expectations to reach around $620 million by 2034. This illustrates a robust growth trajectory, anticipating a compound annual growth rate (CAGR) of about 6.3% during the forecast period from 2025 to 2034. Deflectable Tip Catheter Market The deflectable tip catheter market is poised for significant growth, valued at approximately $2.5 billion in 2024. This market is projected to reach around $4.8 billion by 2034, fueled by advancements in minimally invasive procedures and increased demand for precision in catheter-based interventions. The Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is estimated at 7.1%. Peel-Away Introducer Market The market for peel-away introducers is estimated to reach approximately $250 million in 2024. As medical interventions increasingly embrace minimally invasive techniques, the demand for advanced introducer technologies is expected to grow significantly. The projected market value for 2034 is forecasted to hit around $500 million, indicating robust development driven by continuous innovation and increasing application across various medical procedures. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio
